172 related articles for article (PubMed ID: 14645238)
1. E2F and Sp1/Sp3 Synergize but are not sufficient to activate the MYCN gene in neuroblastomas.
Kramps C; Strieder V; Sapetschnig A; Suske G; Lutz W
J Biol Chem; 2004 Feb; 279(7):5110-7. PubMed ID: 14645238
[TBL] [Abstract][Full Text] [Related]
2. E2F proteins regulate MYCN expression in neuroblastomas.
Strieder V; Lutz W
J Biol Chem; 2003 Jan; 278(5):2983-9. PubMed ID: 12438307
[TBL] [Abstract][Full Text] [Related]
3. E2F-dependent histone acetylation and recruitment of the Tip60 acetyltransferase complex to chromatin in late G1.
Taubert S; Gorrini C; Frank SR; Parisi T; Fuchs M; Chan HM; Livingston DM; Amati B
Mol Cell Biol; 2004 May; 24(10):4546-56. PubMed ID: 15121871
[TBL] [Abstract][Full Text] [Related]
4. Silencing of transcription of the human luteinizing hormone receptor gene by histone deacetylase-mSin3A complex.
Zhang Y; Dufau ML
J Biol Chem; 2002 Sep; 277(36):33431-8. PubMed ID: 12091390
[TBL] [Abstract][Full Text] [Related]
5. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells.
Xiao H; Hasegawa T; Isobe K
J Cell Biochem; 1999 Jun; 73(3):291-302. PubMed ID: 10321829
[TBL] [Abstract][Full Text] [Related]
6. Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells.
Ammanamanchi S; Brattain MG
J Biol Chem; 2004 Jul; 279(31):32620-5. PubMed ID: 15155736
[TBL] [Abstract][Full Text] [Related]
7. DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation.
Milutinovic S; Brown SE; Zhuang Q; Szyf M
J Biol Chem; 2004 Jul; 279(27):27915-27. PubMed ID: 15087453
[TBL] [Abstract][Full Text] [Related]
8. Retinoic acid induced downregulation of MYCN is not mediated through changes in Sp1/Sp3.
Kanemaru KK; Tuthill MC; Takeuchi KK; Sidell N; Wada RK
Pediatr Blood Cancer; 2008 Apr; 50(4):806-11. PubMed ID: 17554788
[TBL] [Abstract][Full Text] [Related]
9. Trichostatin A induces transforming growth factor beta type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1.NF-Y complex.
Huang W; Zhao S; Ammanamanchi S; Brattain M; Venkatasubbarao K; Freeman JW
J Biol Chem; 2005 Mar; 280(11):10047-54. PubMed ID: 15647279
[TBL] [Abstract][Full Text] [Related]
10. Sp1/Sp3-dependent regulation of human telomerase reverse transcriptase promoter activity by the bioactive sphingolipid ceramide.
Wooten LG; Ogretmen B
J Biol Chem; 2005 Aug; 280(32):28867-76. PubMed ID: 15951564
[TBL] [Abstract][Full Text] [Related]
11. Trichostatin A, a histone deacetylase inhibitor, activates the IGFBP-3 promoter by upregulating Sp1 activity in hepatoma cells: alteration of the Sp1/Sp3/HDAC1 multiprotein complex.
Choi HS; Lee JH; Park JG; Lee YI
Biochem Biophys Res Commun; 2002 Aug; 296(4):1005-12. PubMed ID: 12200149
[TBL] [Abstract][Full Text] [Related]
12. Transcription factors of the Sp1 family: interaction with E2F and regulation of the murine thymidine kinase promoter.
Rotheneder H; Geymayer S; Haidweger E
J Mol Biol; 1999 Nov; 293(5):1005-15. PubMed ID: 10547281
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter.
Yokota T; Matsuzaki Y; Miyazawa K; Zindy F; Roussel MF; Sakai T
Oncogene; 2004 Jul; 23(31):5340-9. PubMed ID: 15107822
[TBL] [Abstract][Full Text] [Related]
14. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; PĂ„hlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
15. Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3.
Baek SJ; Horowitz JM; Eling TE
J Biol Chem; 2001 Sep; 276(36):33384-92. PubMed ID: 11445565
[TBL] [Abstract][Full Text] [Related]
16. Identification of the promoter of human transcription factor Sp3 and evidence of the role of factors Sp1 and Sp3 in the expression of Sp3 protein.
Lou Z; Maher VM; McCormick JJ
Gene; 2005 May; 351():51-9. PubMed ID: 15857802
[TBL] [Abstract][Full Text] [Related]
17. Aberrant regulation of survivin by the RB/E2F family of proteins.
Jiang Y; Saavedra HI; Holloway MP; Leone G; Altura RA
J Biol Chem; 2004 Sep; 279(39):40511-20. PubMed ID: 15271987
[TBL] [Abstract][Full Text] [Related]
18. Balance between acetylation and methylation of histone H3 lysine 9 on the E2F-responsive dihydrofolate reductase promoter.
Nicolas E; Roumillac C; Trouche D
Mol Cell Biol; 2003 Mar; 23(5):1614-22. PubMed ID: 12588981
[TBL] [Abstract][Full Text] [Related]
19. Heregulin regulates the ability of the ErbB3-binding protein Ebp1 to bind E2F promoter elements and repress E2F-mediated transcription.
Zhang Y; Hamburger AW
J Biol Chem; 2004 Jun; 279(25):26126-33. PubMed ID: 15073182
[TBL] [Abstract][Full Text] [Related]
20. Differential transcriptional regulation of c-myc promoter through the same DNA binding sites targeted by Sp1-like proteins.
Majello B; De Luca P; Suske G; Lania L
Oncogene; 1995 May; 10(9):1841-8. PubMed ID: 7753559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]